← Back to Search

Enzyme

Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase) for Coronavirus (DAMPENCOVID Trial)

Phase 2
Recruiting
Research Sponsored by Jon Simmons
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 28 days
Awards & highlights

DAMPENCOVID Trial Summary

This trial will test if a drug called Dornase Alpha can help people with respiratory failure caused by COVID-19. The trial will see if the drug is safe and if it can reduce the 28-day mortality rate.

Eligible Conditions
  • Coronavirus

DAMPENCOVID Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~28 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 28 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Mortality at 28 days
Systemic Therapeutic Response
Secondary outcome measures
Legnth of Hospital Stay
Legnth of ICU Stay
Pulmonary Function
+1 more

DAMPENCOVID Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Treatment ArmExperimental Treatment1 Intervention
Patient will receive 2.5mg Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase) aerosolized treatment once every 24 hours for five (5) consecutive days; a total of five (5) doses.
Group II: Placebo Arm 0.9% sodium chloridePlacebo Group1 Intervention
Patient will receive 2.5ml of Sodium Chloride 0.9% aerosolized treatment once every 24 hours for five (5) consecutive days; a total of five (5) doses.

Find a Location

Who is running the clinical trial?

Jon SimmonsLead Sponsor
University of South AlabamaOTHER
42 Previous Clinical Trials
15,890 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure
Jon Simmons 2020. "Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04445285.
All > Covid
~9 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top